Slides
Page 1
www.trajanscimed.com Wednesday, 28 October 2026 2026 Annual General Meeting
Page 2
2 YOUR BOARD Non-Executive Chair John Eales AM Founder, CEO and Executive Director Stephen Tomisich Executive Director Robert Lyon Non-Executive Director Tiffiny Lewin Dr Rohit Khanna Non-Executive Director
Page 3
3 QUESTION PROCESS • To ask a written question select the Q & A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast window HOW TO ASK A QUESTION
Page 4
4 VOTING PROCESS • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed HOW TO VOTE
Page 5
5 Address by the Chairman Mr John Eales, AM
Page 6
6 CEO’s Presentation Mr Stephen Tomisich
Page 7
www.trajanscimed.com 28 October 2026 CEO Update Stephen Tomisich, CEO and Managing Director
Page 8
The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 28 October 2026. The information in the presentation is provided for information purposes only, is in summary form and does not purport to be complete. It should be read in conjunction with Trajan’s other announcements to the ASX, including the FY26 Annual Report, Results announcement, and Appendix 4D. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor, taxation situation or needs of any particular investor. A shareholder, investor or potential investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Trajan and conduct its own investigations and analysis. No representation is made as to the accuracy, completeness or reliability of the presentation. Trajan is not obliged to, and does not represent that it will, update the presentation for future developments. All currency figures are in Australian dollars unless otherwise stated. Totals and change calculations may not equate precisely due to rounding. This presentation contains statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms “believe”, “estimate”, “plan”, “target”, “project”, “anticipate”, “expect”, “intend”, “likely”, “may”, “will”, “could” or “should” or similar expressions, or by discussions of strategy, plans, objectives, targets, goals, future events or intentions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. You are cautioned not to place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Trajan or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. Past performance is also not indicative of future performance, and no guarantee of future returns is implied or given. Nothing contained in this presentation is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of Trajan. By reading this presentation you agree to be bound by the limitations set out in this disclaimer. No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this presentation. To the maximum extent permitted by law, neither Trajan nor any of its related entities, or their respective directors, employees or agents, nor any other person accepts liability for loss arising from the use of or reliance on information contained in this presentation or otherwise arising in connection with it, including without limitation any liability from fault of negligence. Disclaimer
Page 9
9 FY2026 Financial Summary KEY POINTS • Revenue: Reported revenue declined due to forex volatility. Underlying H2 FY26 revenue was impacted by circa $5.0M due to AUD appreciation. • nEBITDA: H2 FY26 nEBITDA increased to $8.1M, up 61.8% from H1 FY26 $5.0M, driven by the realisation of cost efficiency measures. With group H2 nEBITDA rising to $10.5M on a fixed currency basis (AUD adjusted to H1 Forex rates). • Proforma Gross Margin: Reported margin declined during H1. In H2 FY26 it increased to 40.6% (+3.2 pts vs H1), and 41.2% in H2 at H1 Forex rates. • NPATA: Growth of NPATA reflects improved underlying profitability and disciplined cost management, particularly in H2. • AUD appreciation: Sustained appreciation in H2 FY26. Approximately 85% of Trajan revenues derived in USD and EUR. REVENUE & EARNINGS Group Revenue $161.4M [PCP: $166.5M] Down 3.1% Group nEBITDA $13.2M [PCP: $15.5M] Down 14.7% Proforma Gross Margin [PCP: 39.8%] Operating NPATA $2.2M [PCP:$0.8M] Up 191.3% FINANCIAL POSITION Cash $12.6M [PCP $11.9M] Up 6.5% Net Debt $34.6M [PCP: $29.5M] Up17.0% 38.9% Down 0.8pts 1. Operating Net Profit After Tax plus Amortisation (NPATA) is Statutory NPAT excluding restructuring costs, acquisition costs, impact from FECs revaluation, amortisation of acquired intangible assets. 2. nEBITDA is statutory EBITDA excluding restructuring costs, acquisition costs and impact from FECs revaluation. FOREX FY2026 AUD:USD and EUR
Page 10
10 FY27 begins with promising momentum FY27 Q1 Update Management accounts* indicate: • nEBITDA momentum has continued with a result of circa $3.5M in the quarter, taking the rolling 12-month nEBITDA to $16.2M • Net revenue** is up 3.8% compared to FY26 Q1 with: • Components & Consumables up by 5.2% • Disruptive Technologies up by 12.7% • Capital Equipment, still challenged though, down by 1.2% • Net Debt reduced in Q1 by $1.6M (*Unaudited FY27 Q1 financial results) (** Fixed forex rates used for net revenue comparison)
Page 11
11 Operational Improvement Continues As this stage of Project Neptune gains traction, the business becomes leaner and it starts to deliver the intended impact: • Gross Margin, FY27 Q1 proforma %GP above 42%, up 15% on Q1 prior year. • Employee Expense, down 8%+ on Q1 prior year. • Scrap, down 8%+ • Project Neptune continues to drive efficiencies going forward. (unaudited FY27 Q1 financial results) (Source: Trajan Sharewise Webinar 08 Oct 2026 )
Page 12
12 Resilience in Components & Consumables Trajan’s largest Business Segment Annualised revenue, at monthly resolution and fixed forex rates, reveals that post destocking (March 2024), growth rate is back to normal.
Page 13
13 Caution remains about short-term Capital Equipment outlook Confidence in the long-term potential, but still rough waters at present Capital Equipment revenues were mostly flat in Q1, and that is against a relatively weak Q1 in the prior year. The opportunity funnel, both food and pharma related, remains healthy, with several new products scheduled for launch in FY27.
Page 14
14 Science that benefits people, here’s what our customers say: And that’s just from management reports in one month - Aug 2026! Drug discovery for Malaria The University of Dundee's Drug Discovery Unit used Trajan's HDX and HDExaminer software to develop a new way to measure drug–target affinity applied to a malaria parasite target; the method gave complete coverage of the protein and binding strengths across more than 50 regions. Food contamination “Our long-standing partnership with Trajan has played an important role in developing our MOSH MOAH expertise. Based on CHRONECT MOxH solutions, reliable service, and a continuous exchange of technical expertise, our collaboration has grown into a trusted and valuable partnership." Research performance “Some of our samples represent critical research into human health and disease. When samples are irreplaceable, we need consumables we can trust. That's why we choose Trajan syringes for their robustness and accuracy." Treatment monitoring for Epilepsy IRCCS (Bologna, Italy) published a real-world evaluation of Trajan’s VAMS® sampling technology for monitoring of anti- seizure medications. Of 105 people with epilepsy; at-home results showed strong correlation (Pearson’s r ranging from 0.88 - 0.98) compared to in clinic collection. “Patients reported VAMS self-collection as feasible, easy, and well-tolerated.” Breast cancer diagnostics “We used to have so many issues with specimens floating off our previous slides. We switched to the Trajan Series 2 adhesive slides and now have hardly any repeats. We love the Trajan slides.” Environmental analysis “Trajan’s HT8 PCB column is the only column that I can rely on for my POPs analysis. When these columns become scarce, I ask my contacts to find any available column to keep in stock, as I cannot afford to be without one to run our samples.”
Page 15
15 FY27 Guidance Based on the current trajectory and AUD exchange rates we expect in FY27 to achieve: • Net Revenue $162M - $166M. • nEBITDA $16.0M – $17.5M. The mid-point of the revenue projection assumes current FX rates and continued softness in Capital Equipment, hence the 2% implied growth at actual rates. The mid-point of the nEBITDA projection represents a 27% uplift over FY26 as the business continues to expand margins and address cost structures through project Neptune.
Page 16
Business of the Meeting
Page 17
17 Item 1 The first item of business is to receive and consider the Company’s Annual Financial Report, including the Directors’ Report and Audit Report for the year ended 30 June 2026. Note: There is no vote required for this item. Financial Statements and Reports
Page 18
18 Resolution 1 To consider, and if thought fit, to pass the following resolution as an ordinary resolution: “That, for the purposes of Section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report as con tained in the Directors’ Report for the year ended 30 June 2026, be adopted.” Note: The vote on this resolution is advisory only and does not bind the Directors or the Company. Adoption of Remuneration Report
Page 19
19 Proxy Voting Results - Resolution 1 ¹ To be voted in favour of the resolution ² Of proxies cast Adoption of Remuneration Report Number %² For 35,235,784 98.99 Against 298,220 0.84 Open – Chair¹ 50,450 0.14 Other 12,000 0.03 Abstain/Exclude 79,862,981 N/A
Page 20
20 Resolution 2 To consider, and if thought fit, to pass the following resolution as an ordinary resolution: "That, John Eales, who retires in accordance with clause 12.5 of the Company's Constitution and ASX Listing Rule 14.4 and, being eligible, offers himself for re-election, be re-elected as a Director of the Company." Re-election of Mr John Eales as a Director
Page 21
21 Proxy Voting Results - Resolution 2 ¹ To be voted in favour of the resolution ² Of proxies cast Re-election of Mr John Eales as a Director Number %² For 112,978,950 99.08 Against 995,145 0.87 Open – Chair¹ 50,450 0.04 Other 12,000 0.01 Abstain/Exclude 1,422,890 N/A
Page 22
22 Resolution 3 To consider, and if thought fit, to pass the following resolution as an ordinary resolution: "That, Tiffiny Lewin, who retires in accordance with clause 12.5 of the Company's Constitution and ASX Listing Rule 14.4 and, being eligible, offers herself for re-election, be re-elected as a Director of the Company." Re-election of Ms Tiffiny Lewin as a Director
Page 23
23 Proxy Voting Results - Resolution 3 ¹ To be voted in favour of the resolution ² Of proxies cast Re-election of Ms Tiffiny Lewin as a Director Number %² For 114,481,214 99.16 Against 915,145 0.79 Open – Chair¹ 50,450 0.04 Other 12,000 0.01 Abstain/Exclude 626 N/A
Page 24
24 Resolution 4 To consider, and if thought fit, to pass the following resolution as an ordinary resolution: "That, subject to the passing of Resolution 2, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareho lders approve the issue of up to 292,683 Options to Mr John Eales (or his nominee), under the Plan on the basis set out in the Explanatory Memo randum." Grant of Options to Director - Mr John Eales
Page 25
25 Proxy Voting Results - Resolution 4 ¹ To be voted in favour of the resolution ² Of proxies cast Grant of Options to Director - Mr John Eales Number %² For 35,136,286 96.86 Against 1,116,069 3.08 Open – Chair¹ 11,250 0.03 Other 12,000 0.03 Abstain/Exclude 79,183,830 N/A
Page 26
26 Resolution 5 To consider, and if thought fit, to pass the following resolution as an ordinary resolution: ''That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of up to 195,12 2 Options to Dr Rohit Khanna (or his nominee), under the Plan on the basis set out in the Explanatory Memorandum." Grant of Options to Director - Dr Rohit Khanna
Page 27
27 Proxy Voting Results - Resolution 5 ¹ To be voted in favour of the resolution ² Of proxies cast Grant of Options to Director - Dr Rohit Khanna Number %² For 35,142,786 96.88 Against 1,116,069 3.08 Open – Chair¹ 4,750 0.01 Other 12,000 0.03 Abstain/Exclude 79,183,830 N/A
Page 28
28 Resolution 6 To consider, and if thought fit, to pass the following resolution as an ordinary resolution: "That, subject to the passing of Resolution 3, for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareho lders approve the issue of up to 195,122 Options to Ms Tiffiny Lewin (or her nominee), under the Plan on the basis set out in the Explanatory M emorandum." Grant of Options to Director - Ms Tiffiny Lewin
Page 29
29 Proxy Voting Results - Resolution 6 ¹ To be voted in favour of the resolution ² Of proxies cast Grant of Options to Director - Ms Tiffiny Lewin Number %² For 35,136,286 96.88 Against 1,116,069 3.08 Open – Chair¹ 4,750 0.01 Other 12,000 0.03 Abstain/Exclude 79,190,330 N/A
Page 30
www.trajanscimed.com Questions
Page 31
31 Voting and Meeting Close If you have not yet voted, please proceed with voting now. The final results of the meeting will be advised to the ASX and will be available on Trajan’s investor website after the meeting. Thank you for your attendance. Thank you.
Page 32
www.trajanscimed.com 32 Thank you